# Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI

> **NCT05705089** · PHASE3 · COMPLETED · sponsor: **Rajaie Cardiovascular Medical and Research Center** · enrollment: 50 (actual)

## Conditions studied

- Left Ventricular Thrombus
- ST Segment Elevation Myocardial Infarction

## Interventions

- **DRUG:** Rivaroxaban 15 MG
- **DRUG:** Warfarin

## Key facts

- **NCT ID:** NCT05705089
- **Lead sponsor:** Rajaie Cardiovascular Medical and Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-30
- **Primary completion:** 2023-02-01
- **Final completion:** 2023-04-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05705089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05705089, "Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05705089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*